Core Viewpoint - Hansen Pharmaceutical (002412) has responded to investor inquiries regarding its products aimed at improving gastrointestinal function, highlighting a range of offerings in this category [1] Product Offerings - The company, including its wholly-owned subsidiary Yunnan Yongzitang Pharmaceutical Co., Ltd., has several products targeting gastrointestinal health, including: - Si Mo Tang Oral Liquid - Chen Xiang Lu Bai Lu Pian - Ba Wei Rou Gui Jiao Nang - Wei Chang Ling Jiao Nang - Tong Shu Kou Shuang Jiao Nang - Ku Shen Jiao Nang [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 2026年2月9日，汉森制药（sz002412）触及涨停，涨停价8.35元，涨幅10.01%，总市值42.02亿元，流通 市值41.57亿元，截止发稿，总成交额5.55亿元。 根据喜娜AI异动分析，汉森制药涨停原因可能如下，公司治理优化+核心产品优势+现金流改善： 1、汉 森制药近期对公司章程及20余项管理制度进行修订，涵盖董事会运作、信息披露、关联交易等关键领 域，公司治理全面优化，规范性显著提升，信息披露透明度增强。其主导产品四磨汤口服液等为独家品 种，2023年营收占比达81.98%，核心产品竞争力强。 2、2025年三季度公司经营活动现金流同比增长 16.42%，达1.62亿元，现金流状况良好。同时控股股东质押比例从16.28%降至4.72%，显著降低股权质 押风险。国家药监局《中药注册管理专门规定》即将落地，公司主导产品已全部修订完毕，其他产品也 在有序推进，有望受益于行业整顿。 3、从市场表现来看，近期中药板块受政策等因素影响有一定热 度，部分中药股表现活跃。东方财富数据显示，当日中药板块有一定资金流入，形成板块联动效应。 4、技术面上，若该股MA ...

Core Viewpoint - The company, despite a significant decline in stock price and market value, has attracted investment from major players like Goldman Sachs and prominent retail investors, raising questions about its true value in light of recent policy support for the traditional Chinese medicine industry [1][5]. Group 1: Company Performance - The company's main business includes traditional Chinese medicine preparations and chemical drugs, with key products like Si Mo Tang oral solution contributing 54% of revenue and a gross margin of 76%, while Tianma Xingnao capsule accounts for 23% of revenue with an 82% gross margin [3]. - Despite having high-margin products and stable sales, the company has struggled with growth, maintaining revenue below 1 billion and average annual profits around 100 million for years, indicating a lack of scalability and growth potential [3][5]. - The market has penalized the company's stock price due to its stagnant growth, leading to a cycle where low stock prices attract high-risk investors, but without a guarantee of significant future growth [5][9]. Group 2: Market Dynamics - The company faces inherent limitations in market growth for its product categories, particularly in an aging population and saturated chronic disease markets, which restricts its ability to expand revenue significantly [5][9]. - The company's conservative strategic choices, focusing on existing product lines rather than aggressive mergers or cross-industry marketing, hinder its competitiveness during industry upswings [5][9]. Group 3: Investment Perspective - Investors like Goldman Sachs and retail investor Xia Chongyang are focusing on the company's high gross margins, unique products, stable cash flow, and low market valuation, viewing their investments as value bets rather than growth opportunities [7][9]. - The company's recent performance, including a 30% decline in Q3 2025 earnings, raises concerns about its reliance on a few key products for profitability, highlighting the risks associated with such a concentrated revenue stream [7][9]. - The investment strategy of major investors may reflect a contrarian approach, betting on potential recovery driven by policy support, but this requires patience and the ability to withstand prolonged market downturns [9][11]. Group 4: Recommendations for Stakeholders - The company should clearly communicate the reasons behind recent profit declines and outline actionable growth plans, including timelines for new product development and channel expansion [11]. - There is a need for the company to consider capital operations, as its low market value and stable cash flow could make it an attractive target for mergers or acquisitions [11]. - Regulatory bodies should focus on guiding industry compliance and technological investment rather than relying on superficial policy measures to address structural issues within individual companies [11].

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a 2.71% increase in stock price on December 19, with a trading volume of 66.22 million yuan, indicating positive market sentiment [1] - On December 19, Hansen Pharmaceutical had a financing buy amount of 7.61 million yuan and a financing repayment of 10.93 million yuan, resulting in a net financing buy of -3.32 million yuan [1] - As of December 19, the total balance of margin trading for Hansen Pharmaceutical was 146 million yuan, which represents 4.25% of its circulating market value, indicating a relatively high level compared to the past year [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include: Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and others, with a total revenue of 741 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 6.75% [2] - The net profit attributable to the parent company for the same period was 82.53 million yuan, showing a year-on-year decrease of 36.88% [2] Group 3 - Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Hansen Pharmaceutical was 24,100, an increase of 0.85% from the previous period [3] - The eighth largest circulating shareholder is Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, holding 2.11 million shares as a new shareholder [3]

Core Viewpoint - Hansen Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 17.64%, indicating strong market performance and investor interest [2]. Group 1: Stock Performance - As of December 3, Hansen Pharmaceutical's stock price increased by 2.02%, reaching 7.07 CNY per share, with a trading volume of 46.93 million CNY and a turnover rate of 1.35% [1]. - The stock has experienced a 2.61% increase over the last five trading days, a 7.45% increase over the last 20 days, and a 4.74% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Hansen Pharmaceutical reported a revenue of 741 million CNY, reflecting a year-on-year growth of 6.75%. However, the net profit attributable to shareholders decreased by 36.88% to 82.53 million CNY [2]. - The company has distributed a total of 485 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. Group 3: Business Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang, Hunan Province. Its main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The revenue composition of Hansen Pharmaceutical includes: 54.81% from Si Mo Tang oral liquid, 23.38% from Tian Ma Xing Nao capsules, and smaller contributions from various other products [2]. Group 4: Shareholder Information - As of November 28, 2025, the number of shareholders in Hansen Pharmaceutical increased to 24,100, with an average of 20,618 circulating shares per person, a slight decrease of 0.84% from the previous period [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is the eighth largest, holding 2.11 million shares as a new shareholder [3].

Group 1 - The 91st National Pharmaceutical Trade Fair was held in Nanjing from November 19-21, covering over 170,000 square meters with more than 8,200 exhibition booths and over 4,000 domestic and international companies participating [1] - The event featured over 70 forums and activities, with more than 550 industry experts and scholars discussing hot topics and future trends in the pharmaceutical industry [1] - Hunan Hansen Pharmaceutical Co., Ltd., a leading company in Hunan's pharmaceutical sector, showcased its products at the Hunan exhibition area, aiming to promote high-quality development in the industry [1] Group 2 - During the Nanjing Pharmaceutical Trade Fair, Hansen Pharmaceutical's core product, Hansen Si Mo Tang Oral Liquid, was awarded a spot on the "2024-2025 Annual Family Essential Medicine Brand" list due to its excellent efficacy and market reputation [2] - Hansen Pharmaceutical adheres to the corporate value of "treating consumers well and continuously providing good products," aiming to contribute more to the health of the Chinese population [2] - The Si Mo Tang Oral Liquid is a compound traditional Chinese medicine for gastrointestinal motility, included in the national medical insurance catalog and recognized as a protected traditional Chinese medicine product [2]

Company Overview - Hansen Pharmaceutical was established on January 21, 1998, and listed on the Shenzhen Stock Exchange on May 25, 2010. The company is based in Yiyang, Hunan Province, and is a well-known pharmaceutical enterprise in China, focusing on the research and development of traditional Chinese medicine, with its core product, Simiao Decoction Oral Liquid, leading the market share [1] Financial Performance - In the third quarter of 2025, Hansen Pharmaceutical achieved a revenue of 741 million yuan, ranking 47th among 69 industry companies. The industry leader, Baiyunshan, reported a revenue of 61.606 billion yuan, while the second, Yunnan Baiyao, reported 30.654 billion yuan. The industry average revenue was 3.755 billion yuan, with a median of 1.462 billion yuan [2] - The company's net profit for the same period was 82.5252 million yuan, ranking 36th in the industry. The top performer, Yunnan Baiyao, had a net profit of 4.789 billion yuan, and Baiyunshan followed with 3.398 billion yuan. The industry average net profit was 447 million yuan, with a median of 83.6773 million yuan [2] Financial Ratios - Hansen Pharmaceutical's debt-to-asset ratio was 11.77% in the third quarter of 2025, down from 14.33% in the previous year and significantly lower than the industry average of 32.81%. The company's gross profit margin was 77.04%, an increase from 75.13% year-on-year and higher than the industry average of 52.44% [3] Executive Compensation - The chairman and president, Liu Zhengqing, received a salary of 1.7064 million yuan in 2024, an increase of 30,700 yuan from 2023. Liu Zhengqing has a master's degree and has held various positions, including workshop director at Yiyang Pharmaceutical Factory [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders of Hansen Pharmaceutical was 23,300, a decrease of 1.20% from the previous period. The average number of circulating A-shares held per shareholder increased by 1.21% to 21,400 shares. Among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) was the eighth largest, holding 2.114 million shares as a new shareholder [5]

Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant financing balances and a slight decline in net profit [1][2]. Group 2 - On October 16, Hansoh Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 33.34 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 4.74 million yuan, resulting in a net financing buy-in of -1.83 million yuan [1]. - As of October 16, the total financing and securities lending balance for Hansoh Pharmaceutical was 151 million yuan, with the financing balance accounting for 4.61% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, there were no shares repaid or sold on October 16, with the securities lending balance also at 0.00 shares, reflecting a high level compared to the past year [1]. Group 3 - Hansoh Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The main revenue sources for Hansoh Pharmaceutical include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and others, with a diverse product portfolio [2]. - As of August 29, the number of shareholders for Hansoh Pharmaceutical was 23,600, a decrease of 3.43% from the previous period, while the average circulating shares per person increased by 3.55% to 21,113 shares [2]. Group 4 - For the first half of 2025, Hansoh Pharmaceutical achieved an operating income of 509 million yuan, representing a year-on-year growth of 5.91%, while the net profit attributable to the parent company was 68.54 million yuan, a decrease of 31.80% year-on-year [2]. Group 5 - Since its A-share listing, Hansoh Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3].

Group 1 - The company, Hansen Pharmaceutical, has confirmed that its product, Si Mo Tang Oral Liquid, has been selected for procurement in multiple projects, including the Beijing-Tianjin-Hebei "3+N" alliance and the fourth batch of centralized procurement in Fujian [2] - The product has also received selected qualification in the fifth round of drug centralized procurement in Jiangsu Province and has limited procurement qualifications in the Guangdong alliance for Jin Lianhua and other traditional Chinese medicine projects [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a decline in stock price and significant financing activity on August 29, with a net financing outflow of 475.93 million yuan [1] - On August 29, Hansen Pharmaceutical's financing buy-in amounted to 9.87 million yuan, while the financing repayment was 14.63 million yuan, resulting in a total financing balance of 142 million yuan, which represents 4.19% of its market capitalization [1] - The company has a high financing balance, exceeding the 50th percentile level over the past year, indicating a relatively elevated financing position [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and other products, with a total revenue of 5.09 billion yuan for the first half of 2025, reflecting a year-on-year growth of 5.91% [2] - The net profit attributable to the parent company for the same period was 68.54 million yuan, showing a year-on-year decrease of 31.80% [2] Group 3 - Since its A-share listing, Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3]